Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

RETRACTED ARTICLE: SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1

verfasst von: Jiu-Gang Song, Hua-Hong Xie, Nan Li, Kai Wu, Ji-gang Qiu, Da-Ming Shen, Chun-Jin Huang

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

SUMOylation is a post-translational modification exerted various effects on the target proteins. SUMOylation is a highly dynamic and reversible process, which has been shown to play an important role in tumorigenesis. However, the roles of sentrin/SUMO-specific proteases (SENPs), which mediate the reverse process of SUMOylation, in tumorigenesis remains largely unexplored. Here, we uncover a critical role of SENP6 in promoting gastric cancer cells growth via regulating the deSUMOylation of a transcription factor forkhead box protein M1 (FoxM1). We demonstrated that the mRNA and protein levels were elevated in gastric cancer tissues. Overexpression of SENP6 promoted, while RNA interference depletion of endogenous SENP6 inhibited gastric cancer cells growth and the ability of colony formation. By using biochemical assays, we identified FoxM1 as a novel substrate of SENP6 in gastric cancer cells. Thus, our data suggest that SENP6, which is highly expressed in gastric cancer cells, regulates the transcriptional activity and stability of FoxM1 through deSUMOylation.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Zurück zum Zitat Muller S, Ledl A, Schmidt D. Sumo: a regulator of gene expression and genome integrity. Oncogene. 2004;23:1998–2008.CrossRefPubMed Muller S, Ledl A, Schmidt D. Sumo: a regulator of gene expression and genome integrity. Oncogene. 2004;23:1998–2008.CrossRefPubMed
5.
Zurück zum Zitat Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8:947–56.CrossRefPubMed Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8:947–56.CrossRefPubMed
6.
Zurück zum Zitat Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, et al. The sumo pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 2005;9:769–79.CrossRefPubMed Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, et al. The sumo pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 2005;9:769–79.CrossRefPubMed
7.
Zurück zum Zitat Baek SH. A novel link between sumo modification and cancer metastasis. Cell Cycle. 2006;5:1492–5. Georgetown, Tex.CrossRefPubMed Baek SH. A novel link between sumo modification and cancer metastasis. Cell Cycle. 2006;5:1492–5. Georgetown, Tex.CrossRefPubMed
8.
Zurück zum Zitat Mukhopadhyay D, Dasso M. Modification in reverse: the sumo proteases. Trends Biochem Sci. 2007;32:286–95.CrossRefPubMed Mukhopadhyay D, Dasso M. Modification in reverse: the sumo proteases. Trends Biochem Sci. 2007;32:286–95.CrossRefPubMed
9.
Zurück zum Zitat Guo C, Henley JM. Wrestling with stress: roles of protein sumoylation and desumoylation in cell stress response. IUBMB Life. 2014;66:71–7.CrossRefPubMed Guo C, Henley JM. Wrestling with stress: roles of protein sumoylation and desumoylation in cell stress response. IUBMB Life. 2014;66:71–7.CrossRefPubMed
10.
Zurück zum Zitat Shen HJ, Zhu HY, Yang C, Ji F. Senp2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev. 2012;13:3583–7.CrossRefPubMed Shen HJ, Zhu HY, Yang C, Ji F. Senp2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev. 2012;13:3583–7.CrossRefPubMed
11.
Zurück zum Zitat Qian J, Luo Y, Gu X, Wang X. Inhibition of senp6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced nf-kappab activation. Cancer Biother Radiopharm. 2013;28:196–200.CrossRefPubMed Qian J, Luo Y, Gu X, Wang X. Inhibition of senp6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced nf-kappab activation. Cancer Biother Radiopharm. 2013;28:196–200.CrossRefPubMed
12.
Zurück zum Zitat Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A, et al. Susp1 antagonizes formation of highly sumo2/3-conjugated species. J Cell Biol. 2006;174:939–49.CrossRefPubMedPubMedCentral Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A, et al. Susp1 antagonizes formation of highly sumo2/3-conjugated species. J Cell Biol. 2006;174:939–49.CrossRefPubMedPubMedCentral
13.
14.
Zurück zum Zitat Dou H, Huang C, Singh M, Carpenter PB, Yeh ET. Regulation of DNA repair through desumoylation and sumoylation of replication protein a complex. Mol Cell. 2010;39:333–45.CrossRefPubMedPubMedCentral Dou H, Huang C, Singh M, Carpenter PB, Yeh ET. Regulation of DNA repair through desumoylation and sumoylation of replication protein a complex. Mol Cell. 2010;39:333–45.CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Rojas-Fernandez A, Plechanovova A, Hattersley N, Jaffray E, Tatham MH, Hay RT. Sumo chain-induced dimerization activates rnf4. Mol Cell. 2014;53:880–92.CrossRefPubMedPubMedCentral Rojas-Fernandez A, Plechanovova A, Hattersley N, Jaffray E, Tatham MH, Hay RT. Sumo chain-induced dimerization activates rnf4. Mol Cell. 2014;53:880–92.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wierstra I. The transcription factor foxm1 (forkhead box m1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res. 2013;118:97–398.CrossRefPubMed Wierstra I. The transcription factor foxm1 (forkhead box m1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res. 2013;118:97–398.CrossRefPubMed
19.
Zurück zum Zitat Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K, Liu C. Foxm1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 2015;16:23–9.CrossRefPubMed Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K, Liu C. Foxm1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 2015;16:23–9.CrossRefPubMed
20.
Zurück zum Zitat Xu N, Wu SD, Wang H, Wang Q, Bai CX. Involvement of foxm1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev. 2012;13:4739–43.CrossRefPubMed Xu N, Wu SD, Wang H, Wang Q, Bai CX. Involvement of foxm1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev. 2012;13:4739–43.CrossRefPubMed
21.
Zurück zum Zitat Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of forkhead box m1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67:8293–300.CrossRefPubMed Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of forkhead box m1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67:8293–300.CrossRefPubMed
22.
Zurück zum Zitat Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, et al. Uncovering sumoylation dynamics during cell-cycle progression reveals foxm1 as a key mitotic sumo target protein. Mol Cell. 2014;53:1053–66.CrossRefPubMed Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries M, et al. Uncovering sumoylation dynamics during cell-cycle progression reveals foxm1 as a key mitotic sumo target protein. Mol Cell. 2014;53:1053–66.CrossRefPubMed
23.
Zurück zum Zitat Zhang J, Yuan C, Wu J, Elsayed Z, Fu Z. Polo-like kinase 1-mediated phosphorylation of forkhead box protein m1b antagonizes its sumoylation and facilitates its mitotic function. J Biol Chem. 2015;290:3708–19.CrossRefPubMed Zhang J, Yuan C, Wu J, Elsayed Z, Fu Z. Polo-like kinase 1-mediated phosphorylation of forkhead box protein m1b antagonizes its sumoylation and facilitates its mitotic function. J Biol Chem. 2015;290:3708–19.CrossRefPubMed
24.
Zurück zum Zitat McDowall MD, Scott MS, Barton GJ. Pips: human protein-protein interaction prediction database. Nucleic Acids Res. 2009;37:D651–6.CrossRefPubMed McDowall MD, Scott MS, Barton GJ. Pips: human protein-protein interaction prediction database. Nucleic Acids Res. 2009;37:D651–6.CrossRefPubMed
25.
Zurück zum Zitat Wierstra I, Alves J. Foxm1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257–74.PubMed Wierstra I, Alves J. Foxm1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257–74.PubMed
26.
Zurück zum Zitat Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of foxm1 transcription factor: lessons from transgenic mouse models. Cell cycle. 2011;10:396–405. Georgetown, Tex.CrossRefPubMedPubMedCentral Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of foxm1 transcription factor: lessons from transgenic mouse models. Cell cycle. 2011;10:396–405. Georgetown, Tex.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Le Lay J, Kaestner KH. The fox genes in the liver: from organogenesis to functional integration. Physiol Rev. 2010;90:1–22.CrossRefPubMed Le Lay J, Kaestner KH. The fox genes in the liver: from organogenesis to functional integration. Physiol Rev. 2010;90:1–22.CrossRefPubMed
28.
Zurück zum Zitat Chen W, Yuan K, Tao ZZ, Xiao BK. Deletion of forkhead box m1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev. 2011;12:1785–8.PubMed Chen W, Yuan K, Tao ZZ, Xiao BK. Deletion of forkhead box m1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev. 2011;12:1785–8.PubMed
Metadaten
Titel
RETRACTED ARTICLE: SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1
verfasst von
Jiu-Gang Song
Hua-Hong Xie
Nan Li
Kai Wu
Ji-gang Qiu
Da-Ming Shen
Chun-Jin Huang
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3737-z

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.